Journal of International Psychiatry

[Abstract] Objective: To explore the clinical effect of paroxetine treatment on postpartum depression and its impact on neuroendocrine and sleep. Methods: From March 2021 to March 2023, case data were collected and filed. A total of 200 patients with postpartum depression admitted to the hospital were included. The included subjects were divided into a control group (treated with maprotilin) and an observation group (treated with paroxetine) based on a standardized grouping method of "simple randomization", with 100 cases included each; Observe and compare the negative emotions, sleep quality, neuroendocrine function indicators, sexual hormone levels, and incidence of adverse reactions between the two groups. Results: After treatment, the scores of the Edinburgh Postnatal Depression Scale (EPDS) and the Pittsburgh Sleep Quality Index (PSQI) decreased in both groups, and the scores in the observation group were significantly lower (P<0.05); After treatment, the levels of serum cortisol (Cor) and renal stimulating hormone releasing hormone (ACTH) decreased and the levels of 5-hydroxytryptamine (5-HT) increased in both groups, with patients in the observation group being better (P<0.05); After treatment, the levels of serum estradiol (E2) and progesterone (P) in both groups increased, while the levels of prolactin (PRL) decreased, and the observation group was more significant than the control group (P<0.05); The incidence of adverse reactions was compared between the two groups (P>0.05). Conclusion: Paroxetine can play a role in regulating the levels of neurotrophic factors and sexual hormones in patients with postpartum depression, significantly improving the degree of depression and further improving their sleep quality.

[Key words] Postnatal depression; Paroxetine; Clinical effects; Neuroendocrine; sleep